Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Brain : a journal of neurology·2026

Same author

Complications, outcomes, and implications of a prolonged vegetative state in anti-NMDA receptor encephalitis: a retrospective international cohort study.

The Lancet. Neurology·2026

Same author

[Neurology : what's new in 2025].

Revue medicale suisse·2026

Same author

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Brain : a journal of neurology·2025

Same author

Unravelling the complex inflammatory landscape of COVID-19 infection: a pathway to biomarkers identification in infection-associated delirium in the ICU.

Intensive care medicine experimental·2025

Same author

Neuron-reactive KIR<sup>+</sup>CD8<sup>+</sup> T cells display an encephalitogenic transcriptional program in autoimmune encephalitis.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: May 9, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Assessing risks of multiple sclerosis therapies.

Valeriy Parfenov¹, Myriam Schluep, Renaud Du Pasquier

¹Service of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, 46 rue du Bugnon, Lausanne, Switzerland.

Journal of the Neurological Sciences

|July 10, 2013

Summary

Multiple sclerosis (MS) treatments have advanced, but managing diverse drug risks is challenging. This review guides clinicians on monitoring serious adverse events for optimal patient safety in MS therapy.

Keywords:

Complications Drug approval Monitoring Multiple sclerosis Safety Treatment

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: May 9, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

Neurology
Pharmacology
Clinical Medicine

Background:

Multiple sclerosis (MS) has transitioned from untreatable to manageable with pharmaceutical advancements.
The increasing number of MS therapies presents a challenge in comparing risk-benefit profiles for personalized treatment.

Purpose of the Study:

To review the safety profiles of current multiple sclerosis (MS) therapies.
To focus on serious, medication-specific adverse events and provide guidance for clinical safety monitoring.
To discuss future directions in risk management and drug approval for MS.

Main Methods:

Systematic review of safety data for pharmaceutical agents used in multiple sclerosis (MS).
Focus on serious adverse events, excluding teratogenicity (unless black box warning) and hypersensitivity reactions.
Analysis of current risk management strategies and potential improvements in drug approval processes.

Main Results:

Summary of safety profiles for various MS medications, highlighting significant potential adverse events.
Identification of key areas for clinician attention in patient safety monitoring.
Discussion of limitations in current risk management and drug approval models.

Conclusions:

Effective management of multiple sclerosis (MS) requires careful consideration of individual drug safety profiles.
Enhanced safety monitoring protocols are crucial for patients undergoing MS treatment.
Future strategies should aim to improve drug approval processes and overall patient safety in MS care.